Merck KGaA, Darmstadt, Germany, has acquired HUB Organoids Holding B.V. for an undisclosed amount, marking a significant expansion of its Life Science business. This strategic acquisition sees a global leader in adult stem cell-derived organoids joining a prominent science and technology company, further strengthening Merck KGaA's capabilities in advanced biological research and development.
HUB Organoids is at the forefront of developing patient-derived "mini-organs in a dish" from both healthy and diseased tissues. This patented technology represents a paradigm shift for drug discovery and development, offering highly predictive models for preclinical patient stratification, predictive diagnostics, personalized medicine, and clinical trials. HUB provides licenses to its proprietary technology and services from its organoid biobank, supporting advancements across therapeutic areas including oncology, immuno-oncology, inflammatory diseases, genetic diseases, infectious diseases, and toxicology.
For Merck KGaA's Life Science business, the acquisition of HUB Organoids directly expands its Next-Gen Biology Portfolio. The integration of HUB’s expertise will enable Merck KGaA to offer enhanced solutions that address critical challenges in drug development, specifically by reducing drug attrition and improving the prediction of patient responses to treatment. This strategic alignment aims to close the gap between laboratory findings and clinical outcomes, leveraging the precision of organoid models for more efficient and effective therapeutic breakthroughs.
The combined entity is expected to accelerate innovation in life sciences by providing researchers and pharmaceutical companies with state-of-the-art tools and services. This acquisition empowers Merck KGaA to further contribute to the development of next-generation therapeutics, offering more reliable models that can advance personalized medicine and ultimately bring new treatments to patients faster and with greater confidence.